1. Etoposide radiosensitizes p53-defective cholangiocarcinoma cell lines independent of their G2 checkpoint efficacies
- Author
-
Sopit Wongkham, Kitsana Utapom, Sutiwan Meethang, Arunee Hematulin, and Daniel Sagan
- Subjects
Cancer Research ,Cell cycle checkpoint ,business.industry ,medicine.medical_treatment ,Cell ,Cancer ,G2-M DNA damage checkpoint ,Cell cycle ,medicine.disease ,Radiation therapy ,medicine.anatomical_structure ,Oncology ,Cancer cell ,Cancer research ,Medicine ,business ,Etoposide ,medicine.drug - Abstract
Radiotherapy has been accounted as the most comprehensive cancer treatment modality over the past few decades. However, failure of this treatment modality occurs in several malignancies due to the resistance of cancer cells to radiation. It was previously reported by the present authors that defective cell cycle checkpoints could be used as biomarkers for predicting the responsiveness to radiation in individual patients with cholangiocarcinoma (CCA). However, identification of functional defective cell cycle checkpoints from cells from a patient's tissues is cumbersome and not applicable in the clinic. The present study evaluated the radiosensitization potential of etoposide in p53-defective CCA KKU-M055 and KKU-M214 cell lines. Treatment with etoposide enhanced the responsiveness of two p53-defective CCA cell lines to radiation independent of G2 checkpoint function. In addition, etoposide treatment increased radiation-induced cell death without altering the dominant mode of cell death of the two cell lines. These findings indicate that etoposide could be used as a radiation sensitizer for p53-defective tumors, independent of the function of G2 checkpoint.
- Published
- 2018
- Full Text
- View/download PDF